1. 1. Abou-Alfa GK, Johnson P, Knox J, Davidenko I, Lacava J, Leung T, Mori A, Le Berre M, Voliotis D, Saltz L (2008) Final results from a phase II (PhII), randomized, double-blind study of sorafenib plus doxorubicin (S+D) versus placebo plus doxorubicin (P+D) in patients
2. 2. (pts) with advanced hepatocellular carcinoma. In 2008 Gastrointestinal Cancers Symposium Abstract 128. American Society of Oncology, 25-27 January 2008, Orlando, FL, USA, p132
3. 3. Alberts SR, Morlan BW, Kim GP, Pitot HC, Quevedo FJ, Dakhil SR, Gross HM, Merchan JR, Roberts RL (2007) NCCTG phase II trial (N044J) of AZD2171 for patients with hepatocellular carcinoma
4. 4. (HCC) - Interim review of toxicity. In Gastrointestinal Cancers Symposium Abstract 186. American Society of Oncology, 19-21 January 2007, Orlando, FL, USA, p178
5. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J, Burock K, Zou J, Voliotis D, Guan ZZ (2008) Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma. J Clin Oncol 26: 4509